Law360, New York (October 19, 2009) -- Mylan Inc. and several other pharmaceutical companies will pay a combined sum of $124 million to settle allegations that they bilked state Medicaid programs of millions of dollars by improperly classifying certain drugs for rebate purposes.
The U.S. Department of Justice on Monday announced the settlement, which resolves pending litigation in the U.S. District Court for the District of New Hampshire. The case, initially filed as...
